11.00p+0.00 (+0.00%)20 Dec 2024, 16:01
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Scancell Holdings PLC Fundamentals

Company NameScancell Holdings PLCLast Updated2024-12-20
IndustryBiotechnologySectorHealthcare
Shares in Issue1.037 bnMarket Cap£102.26 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.01EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.8426Debt Equity Ratio0
Asset Equity Ratio-6.7264Cash Equity Ratio-4.2274
Quick Ratio2.3191Current Ratio3.42
Price To Book Value0ROCE0

Scancell Holdings PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Scancell Holdings PLC Company Financials

Assets2024202320222021
Tangible Assets£1.71 m£2.25 m£2.74 m£975,000.00
Intangible Assets000£3.42 m
Investments0000
Total Fixed Assets£1.71 m£2.25 m£2.74 m£4.39 m
Stocks0000
Debtors00£647,000.00£968,000.00
Cash & Equivalents£14.82 m£19.92 m£28.73 m£41.11 m
Other Assets0000
Total Assets£23.58 m£26.86 m£35.11 m£49.06 m
Liabilities2024202320222021
Creditors within 1 year£6.39 m£7.97 m£6.65 m£2.29 m
Creditors after 1 year£20.69 m£28.53 m£27.06 m£38.08 m
Other Liabilities0000
Total Liabilities£27.08 m£36.50 m£33.71 m£40.37 m
Net assets-£3.50 m-£9.65 m£1.39 m£8.69 m
Equity2024202320222021
Called up share capital£929,000.00£819,000.00£815,000.00£815,000.00
Share Premium£71.93 m£60.70 m£60.53 m£65.02 m
Profit / Loss-£9.12 m-£14.30 m-£6.27 m-£16.80 m
Other Equity-£3.50 m-£9.65 m£1.39 m£8.69 m
Preference & Minorities0000
Total Capital Employed-£3.50 m-£9.65 m£1.39 m£8.69 m
Ratios2024202320222021
Debt Ratio00£0.93£0.64
Debt-to-Equity00£12.41£1.75
Assets / Equity-6.7264-6.7264-6.7264-6.7264
Cash / Equity-4.2274-4.2274-4.2274-4.2274
EPS-£0.01-£0.01-£0.01-£0.02
Cash Flow2024202320222021
Cash from operating activities-£15.66 m-£8.14 m-£10.19 m-£7.80 m
Cashflow before financing-£5.27 m-£8.89 m-£11.12 m£38.28 m
Increase in Cash-£5.09 m-£8.80 m-£12.38 m£37.53 m
Income2024202320222021
Turnover0£5.27 m00
Cost of sales0£525,000.0000
Gross Profit0£4.75 m00
Operating Profit-£18.27 m-£11.92 m-£13.30 m-£8.83 m
Pre-Tax profit-£9.12 m-£14.30 m-£6.27 m-£16.80 m

Scancell Holdings PLC Company Background

SectorHealthcare
ActivitiesScancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
Latest Interim Date30 Jan 2024
Latest Fiscal Year End Date24 Sep 2024

Scancell Holdings PLC Directors

AppointedNamePosition
2018-08-31Ms. Kate Cornish-Bowden Non-Executive Director
2016-09-16Mr. David Eric EvansNon-Executive Director,Chairman
2014-05-09Mr. Peter Vance AllenNon-Executive Director
2023-02-01Dr. John ChiplinExecutive Director,Chairman
2024-11-18Professor Linda Gillian DurrantExecutive Director,Chief Executive Officer and Chief Scientific Officer
2024-09-24Dr. Richard Morley GoodfellowNon-Executive Director
2012-12-12Mr. Nigel James Forrester EvansNon-Executive Director,Company Secretary
2013-02-27Mr. Thomas Michael RipponNon-Executive Director
2019-10-31Dr. Matthew Gerrard Winston FrohnNon-Executive Director
2024-09-24Mr. Martin Henry Diggle Non-Executive Director
2024-02-05Dr. Sally Elizabeth AdamsExecutive Director,Development Director
2021-07-28Dr. Clifford Michael HollowayExecutive Director,Chief Executive Officer
2024-09-24Ms. Susan Elizabeth Clement-DaviesNon-Executive Director,Deputy Chairman
2024-09-24Dr. Jean Michel CosseryExecutive Director,Chairman
2024-12-10Mr. Sath NirmalananthanExecutive Director,Chief Financial Officer

Scancell Holdings PLC Contact Details

Company NameScancell Holdings PLC
AddressRobert Robinson Avenue, John Eccles House, Oxford Science Park, Oxford, OX4 4GP
Telephone+44 1865338069
Websitehttps://www.scancell.co.uk

Scancell Holdings PLC Advisors

Nominated AdviserPanmure Gordon (UK) Ltd
Phone+44 2078862500
StockbrokerPanmure Gordon (UK) Ltd
Phone+44 2078862500
Financial PR AdviserFTI Consulting Inc
Phone+44 2037271000
Fax+44 2037271007
SolicitorLaytons
Phone(020) 7842 8000
Fax(020) 7842 8080
RegistrarS.L.C Registrars Ltd
Phone+44 1903706150
Financial PR AdviserVisible Value LLP
AuditorChampion Accountants LLP
Phone(01244) 404 420
Fax(01244) 404 440